Researchers at Vanderbilt University Medical Center, Purdue University, and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent acute flaccid myelitis (AFM), a polio-like illness in children linked to a respiratory viral infection.

AFM, causes sudden weakness in the arms and legs following a fever or respiratory illness. More than 600 cases have been identified since the U.S. Centers for Disease Control and Prevention began tracking the disease in 2014.

There is no specific treatment for AFM, which tends to strike in the late summer or early fall. However, the disease has recently been linked to a group of respiratory viruses called enterovirus D68 (EV-D68), a media release from Purdue University notes.

In the study, published in Science Immunology, researchers at the Vanderbilt Vaccine Center isolated antibody-producing blood cells from the blood of children who had previously been infected by EV-D68. By fusing the blood cells to fast-growing myeloma cells, the researchers were able to generate a panel of monoclonal antibodies that potently neutralized the virus in laboratory studies.

Colleagues at Purdue determined the structure of the antibodies, which shed light on how they specifically recognize and bind to EV-D68. One of the antibodies protected mice from respiratory and neurologic disease when given either before or after infection by the enterovirus.

Related Content:
Acute Flaccid Myelitis Doesn’t Stop Teen from Pursuing Her Music Dreams
Acute Flaccid Myelitis Cause Remains Elusive
Enterovirus Detected in AFM Kids, Suggesting Disease is Viral

“We were excited to isolate potent human antibodies that inhibit this devastating polio-like virus, and these studies will form the basis for taking them forward to clinical trials,” says Dr James Crowe, director, Vanderbilt Vaccine Center; Ann Scott Carell Chair and professor of Pediatrics and Pathology, Microbiology and Immunology in the Vanderbilt University School of Medicine.

“Studying infectious disease from a very basic level and applying the results in an animal model of disease is very powerful; hopefully, our studies will translate to a future therapeutic for this disease in children,” comments Richard Kuhn, Purdue’s Trent and Judith Anderson Distinguished Professor in Science; Krenicki Family Director, Purdue Institute of Inflammation, Immunology and Infectious Disease, the release continues.

[Source(s): Purdue University, EurekAlert]